RUNX2 Antibody

1. Research suggests that miR-23b is involved in TNF-alpha-mediated reduction of bone marrow mesenchymal stem cell osteogenesis by targeting RUNX2. PMID: 29234953
2. Studies have indicated that cross-talk between cAMP/PKA signaling and RUNX2 promotes a malignant phenotype in glioma cells. PMID: 30203400
3. A study identified RUNX2 as a target of miR-217, which directly binds to RUNX2 mRNA and inhibits its expression in bladder cancer cells. Furthermore, findings demonstrated that RUNX2 expression is upregulated by hsa_circ_0000144. Rescue assays revealed that RUNX2 is a downstream effector molecule of the hsa_circ_0000144/miR-217 network. These results highlight the oncogenic role of RUNX2 in bladder neoplasm. PMID: 30098434
4. In summary, these results indicate that PTHLH expression is a poor prognosis marker in head and neck squamous cell carcinoma patients, and the RUNX2-PTHLH axis contributes to tumor growth in these cancers. PMID: 28120940
5. Knockdown of RUNX2 significantly inhibited TE-1 and EC-109 cell viability, repressed TE-1 cell migration and invasion, and increased TE-1 cell apoptosis. These effects were associated with the activation of the PI3K/AKT and ERK pathways. PMID: 30138923
6. Results indicate that RUNX2 gene silencing increased gemcitabine (GEM) sensitivity in p53-mutated pancreatic cancer (PaCa) MiaPaCa2 spheres, suggesting that RUNX2 is involved in PaCa-GEM resistance in the presence of mutated p53. PMID: 29620279
7. Runx2 overexpression effectively decreased TNF-alpha-induced Bax and cleaved caspase-3 expression levels. PMID: 29129496
8. RUNX2 is a promising molecular target for treating patients with pancreatic cancer, regardless of their p53 status. PMID: 29558908
9. Researchers identified a novel missense mutation of RUNX2 in two patients through Whole exome sequencing and demonstrated potential correlations between facial phenotypes and missense mutations in the Runt domain through a mini-meta analysis. PMID: 30095610
10. Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis. PMID: 29242628
11. Results show that RUNX2 is highly expressed in bladder cancer tissues and negatively correlated with miR-154 levels. This is likely due to miR-154 binding the 3'-UTR of RUNX2 mRNA, promoting its degradation. PMID: 29048677
12. Findings identified a novel mutation in addition to previously known mutations in one patient with cleidocranial dysplasia (CCD). The G462X mutation in exon 8 is located in the C-terminus of the proline/serine/threonine-rich (PST) domain. This mutation may reduce Runx2 transacting activity, lower protein stability, downgrade the expression of bone marker genes, and ultimately diminish osteoblast differentiation in CCD patients. PMID: 28703881
13. Findings reveal a novel mechanism where Runx2 is transcriptionally regulated by HSP90 via the AKT/GSK-3beta/beta-catenin signaling pathway, leading to apoptosis of osteosarcoma cells. PMID: 28681940
14. A study identified a novel missense mutation (c.895 T>C, Y299H) in exon 5 of the Runx2 gene in patients with cleidocranial dysplasia (CCD). This mutation results in an amino acid change at codon 895 (P.Tyr 299 His.) from a tryptophan codon (TAT) to a histidine codon (CAT). PMID: 29058294
15. miR-539 acts as a tumor suppressor in colorectal cancer, at least partly, by targeting RUNX2. PMID: 28938522
16. These results indicate that activation of DLX5 and RUNX2 via its distal promoter is a unique feature of growth factors and is important for extracellular matrix regulation. Down-regulation of these transcription factors in periodontitis-associated fibroblasts could be linked to their property to degrade collagen, which may impact the process of periodontitis. PMID: 27645561
17. Down-regulated miR-143-5p promotes the differentiation of dental pulp stem cells into odontoblasts by enhancing Runx2 expression via the OPG/RANKL signaling pathway. PMID: 28608628
18. Three novel mutations (R193G, 258fs, Y400X) have been identified in cleidocranial dysplasia. PMID: 28505335
19. Runx2 is one of the genes responsible for the pathogenesis of osteoarthritis (OA) because RUNX2 is up-regulated in chondrocytes in OA cartilage, and a germline haplodeficiency or deletion of Runx2 in articular chondrocytes decelerates OA progression. PMID: 29356961
20. Application of dexamethasone reduced the expression of RUNX2 and beta-catenin in human gingiva-derived mesenchymal stem cells. PMID: 28459354
21. Runt-related transcription factor 2 (RUNX2) was directly negatively regulated by miR-203. PMID: 28525948
22. Prolactin induction of VEGF-C and Runx2 was partly inhibited by Carboxypeptidase-D inhibitors, implicating nitric oxide, produced by PRL-regulated Carboxypeptidase-D, in breast cancer progression. PMID: 28364216
23. This is the novel report demonstrating that Runx2 expression in mesenchymal stem cells is synergistically influenced by the elasticity of hydrogels and their manner of ephrinB2 immobilized. PMID: 28300720
24. Osterix and RUNX2 are transcriptional regulators of sclerostin in human bone. PMID: 27154028
25. High RUNX2 expression is associated with invasive and metastatic potentials of gastric cancer. PMID: 27007162
26. These findings suggest possible involvement of RUNX2-rs194328 in the etiology of nonsyndromic cleft lip with or without palate (NS-CL+/-P) in Korean cleft-parent trios without excess parental transmission. PMID: 23909516
27. WWOX expression was strongly inhibited in human lung cancers and lung cancer cell lines. Reintroducing WWOX into lung cancer cells inhibited their invasive phenotype through downregulating RUNX2 and its target genes, including MMP-9 expression. PMID: 27834355
28. Research strongly suggests that RUNX2 might be a key player in receptor tyrosine kinase (RTK)-based autocrine loops and a mediator of resistance to BRAF V600E inhibitors involving RTK upregulation in melanoma. PMID: 27102439
29. Thus, WNT/beta-catenin activation is required for RUNX2 expression in at least some osteosarcoma cell types, where RUNX2 is known to promote expression of metastasis-related genes. PMID: 28370561
30. The miR-105/Runx2 axis mediates FGF2-induced ADAMTS expression in osteoarthritis cartilage. PMID: 26816250
31. Regulation of gal-3 expression was strongly correlated with runx2 transcription factor in human thyroid carcinoma. PMID: 28390192
32. Studies investigated the association of runt-related transcription factor 2 (RUNX2) polymorphisms with susceptibility and prognosis of ossification of the posterior longitudinal ligament. PMID: 27704615
33. Data show that BRD4 controls RUNX2 by binding to the enhancers (ENHs), and each RUNX2 ENH is potentially controlled by a distinct set of transcription factors with c-JUN as the principal pivot of this regulatory platform. PMID: 28981843
34. TGF-beta1 stimulates the phosphorylation of Runx2 at three serine amino acids, and this event is required for MMP-13 expression in osteoblastic cells. PMID: 28419442
35. TP (thymidine phosphorylase) curbed the expression of three proteins – IRF8, RUNX2, and osterix. This downregulation was epigenetically driven: High levels of 2DDR, a product of TP secreted by myeloma cells, activated PI3K/AKT signaling and increased the methyltransferase DNMT3A's expression. PMID: 27658717
36. Overexpression of miR-196b suppressed cell viability, migration, invasion, and induced apoptosis, as well as inhibited TGF-beta-induced epithelial mesenchymal transition in A549 cells. Runx2 is a putative target of miR-196b, and Runx2 silencing remarkably increased cell apoptosis and abolished the promotive effects of miR-196b suppression on cell viability, migration, and invasion. PMID: 28950255
37. Runx2 promotes autophagy in metastatic breast cancer cells by increasing acetylation of alpha-tubulin subunits of microtubules. PMID: 28345763
38. Mutation in the RUNX2 gene is associated with acute myeloid leukemia patients with lympho-myeloid clonal hematopoiesis. PMID: 27881874
39. Current observations strongly suggest that the RUNX2/mutant p53/TAp63-regulatory axis is one of the key determinants of SAHA sensitivity in p53-mutated pancreatic cancer cells. PMID: 28671946
40. All three novel RUNX2 mutations significantly reduced the transactivation activity of RUNX2 on the osteocalcin promoter. PMID: 28738062
41. Taken together, these results identify a crucial role for the RUNX cluster in the maintenance and progression of cancer cells and suggest that modulation of the RUNX cluster using the PI polyamide gene-switch technology is a potential strategy to control malignancies. PMID: 28530640
42. miR-466-mediated attenuation of RUNX2 as a novel therapeutic approach to regulate prostate cancer growth, particularly metastasis to bone. PMID: 28125091
43. miR-203 plays a crucial role in suppressing heterotopic ossification by directly targeting Runx2. PMID: 27787524
44. Mechanical load upregulates expression of the Runx2 gene via potentiation of the PC1-JAK2/STAT3 signaling axis, potentially controlling osteoblastic differentiation and ultimately bone formation. PMID: 27699453
45. Runx2 knockdown cells displayed activation of AMP-activated protein kinase (AMPKalpha), the sensor of cellular metabolism. Importantly, Runx2 knockdown in bone-derived cells resulted in increased sensitivity to both Erk1/2 inhibition and AMPKalpha activation by PD184161 and metformin, respectively, despite increased IGF-1Rbeta and AMPKalpha levels. PMID: 26804175
46. RUNX2 mutation disrupts the modulatory effects of dental follicle cells and periodontal ligament cells on the differentiation of osteoclasts and osteoblasts, thereby interfering with bone remodeling. These effects may contribute, in part, to the pathological manifestations of retention of primary teeth and delayed eruption of permanent teeth in patients with cleidocranial dysplasia. PMID: 27509906
47. RUNX2/P57 gene expression is strongly activated, in a process accompanied by enrichment of activating histone marks (H3K4me3, H3ac, and H3K27ac) at the P1 promoter region, to control osteogenic lineage commitment of umbilical cord-derived mesenchymal stem cells. PMID: 27689934
48. Research provides evidence to show that CBX4 may serve as a tumor suppressor in colorectal carcinoma by recruiting HDAC3 to the Runx2 promoter to impede Runx2 expression. PMID: 27864346
49. This research suggests an adhesion-dependent mechanism of RUNX2 for the osteotropism and bone colonization of breast cancer cells and implicates RUNX2 and integrin alpha5 as potential molecular markers for predicting bone metastasis. PMID: 27317874

Show More

Hide All

HGNC: 10472

OMIM: 119600

KEGG: hsa:860

STRING: 9606.ENSP00000360493

UniGene: Hs.535845